Skip to NavigationSkip to content

News

The FDA has cautiously allowed Cellectis to reopen its Phase 1 clinical trial, after a patient death in the previous stage, but has laid down a list...
Research, published in the Journal of Women’s Health, that aimed to determine the effects of the FDA’s guidance on the inclusion of women and ethnic...
Novartis has revealed that its immunotherapy drug Kisqali (ribociclib) met its primary endpoint of progression-free survival in its second Phase 3...
For every completed survey, £5 will be donated to charity. We invite you to participate in this short industry-wide survey which seeks to...
New research has allowed the development of breath test for malaria that could allow a cheaper, more practical solution in rural areas that currently...
The FDA has announced the approval of Roche’s Zelboraf (vemurafenib) in the treatment of Erdheim-Chester Disease (ECD), expanding its already...
Sanofi spent more than $1.5 billion and two decades to develop the first ever vaccine for dengue fever, only a few years after approval, however, it...
Valeant has taken a $1 billion blow to offload a female libido-increasing pill that managed only $10 million in sales during 2016.
Merck KGaA released results of its osteoarthritis treatment that could become the first treatment to successfully slow or halt the disease.
Valeant has had precious little to be happy about over the last few years, it’s bounced from one piece of bad news to another; however, it has...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches